thorough
preclin
visit
includ
follow
element
review
itinerari
review
past
medic
histori
chronic
medic
administr
appropri
immun
advic
prevent
selftreat
common
travelrel
infect
assembl
medic
kit
provis
prescript
medic
record
relev
itinerari
review
includ
date
travel
specif
site
travel
eg
citi
region
includ
layov
itinerari
review
lodg
arrang
style
trip
also
assess
instanc
differ
risk
factor
travel
stay
larg
hotel
franchis
spa
travel
stay
youth
hostel
trekker
camp
addit
risk
travel
resid
area
substanti
period
increas
shortstay
travel
health
assess
includ
review
past
medic
histori
focus
condit
might
affect
travel
instanc
pulmonari
diseas
air
travel
coagulopathi
long
period
sit
current
prescript
review
refil
ensur
patient
adequ
suppli
appropri
medic
travel
patient
antiretrovir
medic
immunosuppress
organ
transplant
take
suppli
equal
twice
anticip
quantiti
pill
need
durat
travel
specif
consider
immunosuppress
patient
cover
separ
section
insur
coverag
travel
visit
vari
insur
carrier
appropri
bill
code
insur
plan
allow
bill
new
establish
patient
evaluationmanag
em
servic
travel
medicin
visit
patient
refer
primari
care
physician
plan
allow
bill
outpati
consult
em
servic
code
patient
need
contact
insur
visit
see
servic
cover
immun
integr
part
pretravel
visit
multipl
factor
taken
consider
includ
travel
destin
climat
travel
durat
sever
potenti
diseas
versu
risk
advers
effect
vaccin
activ
plan
whether
trip
urban
rural
remot
medic
care
time
remain
departur
vaccin
avail
cost
number
dose
need
histori
allergi
vaccin
compon
pregnanc
immunosuppress
box
multipl
inact
vaccin
conveni
effect
administ
singl
clinic
visit
administr
multipl
live
vaccin
sequenti
impair
immun
respons
therefor
given
either
simultan
separ
least
week
interrupt
vaccin
seri
requir
restart
seri
gener
seri
resum
last
administ
dose
instanc
patient
receiv
hepat
b
seri
receiv
first
second
inject
appropri
interv
month
miss
shot
patient
receiv
soon
conveni
without
restart
seri
de
novo
us
center
diseas
control
cdc
divid
immun
routin
requir
recommend
routin
vaccin
necessari
protect
diseas
potenti
risk
mani
part
world
instanc
influenza
tetanu
patient
may
need
booster
especi
tetanu
pertussi
diphtheria
requir
vaccin
intern
health
regul
intern
legal
entiti
subscrib
member
state
world
health
organ
yellow
fever
travel
specif
countri
subsaharan
africa
tropic
south
america
saudi
arabian
govern
requir
meningococc
vaccin
annual
travel
hajj
ritual
pilgrimag
mecca
made
million
muslim
annual
recommend
vaccin
may
protect
travel
diseas
present
part
world
prevent
import
nonendem
infecti
diseas
travel
return
home
recommend
chang
frequent
uptod
inform
found
cdc
web
site
http
wwwcdcgovvaccin
exampl
recommend
vaccin
depend
travel
destin
includ
hepat
typhoid
fever
meningococcu
japanes
enceph
tabl
imposs
tell
food
water
safe
travel
educ
prevent
selftreat
travel
diarrhea
passiv
activ
precaut
passiv
action
includ
avoid
tap
water
ice
salad
unpasteur
dairi
product
thinskin
fruit
raw
seafood
activ
measur
includ
drink
boil
water
carbon
beverag
use
portabl
water
filter
iodin
chlorin
alon
inadequ
elimin
enter
pathogen
take
bismuth
prophylact
shown
provid
protect
diarrhea
although
tab
must
use
time
day
achiev
anticip
efficaci
less
frequent
lower
dose
still
provid
protect
efficaci
may
reduc
studi
probiot
prophylaxi
travel
diarrhea
variabl
inconclus
antibiot
prophylaxi
travel
diarrhea
gener
inappropri
healthi
host
counsel
selfmanag
travel
diarrhea
invalu
mild
case
defin
unform
stool
hour
may
requir
treatment
oral
fluid
maintain
hydrat
sever
case
benefit
antibiot
treatment
selftreat
antibiot
gener
improv
symptom
within
hour
cochran
metaanalysi
found
antibiot
reduc
durat
sever
travel
diarrhea
choic
antibiot
durat
treatment
depend
locat
travel
otherwis
healthi
travel
reason
provid
cours
ciprofloxacin
mg
twice
day
instruct
take
unform
stool
count
exce
per
day
associ
gastrointestin
symptom
fever
shorter
cours
ciprofloxacin
also
prove
effect
patient
counsel
symptom
need
reassess
first
hour
resolv
cours
shorten
otherwis
complet
cours
advis
patient
travel
southeast
asian
countri
quinoloneresist
campylobact
preval
check
cdc
web
site
uptod
resist
pattern
azithromycin
prefer
antimicrobi
agent
patient
azithromycin
mg
mouth
provid
rifaxamin
altern
otherwis
uncompl
travel
diarrhea
healthi
host
howev
firstlin
therapi
concern
decreas
efficaci
sever
case
area
insectborn
diseas
signific
risk
travel
wear
protect
cloth
use
bed
net
n
ndiethylmetatoluamid
deet
type
insect
repel
found
inferior
length
effect
directli
relat
concentr
deet
exampl
deet
effect
approxim
hour
wherea
effect
minut
permethrinbas
insecticid
spray
cloth
bed
net
decreas
risk
mosquito
tick
bite
malaria
deserv
special
mention
infect
approxim
european
north
american
travel
per
year
infecti
diseas
societi
america
idsa
recommend
abcd
approach
malaria
stand
riskawar
risk
contract
malaria
vari
destin
season
climat
altitud
number
mosquito
bite
uptod
inform
avail
cdc
web
site
b
biteavoid
see
earlier
discuss
avoid
insect
bite
gener
c
chemoprophylaxi
complianc
prophylaxi
recommend
travel
endem
area
prophylaxi
medic
suppress
malaria
kill
asexu
blood
stage
parasit
caus
diseas
therefor
protect
level
must
present
parasit
emerg
liver
effect
prophylaxi
must
start
first
possibl
exposur
continu
period
last
potenti
mosquito
bite
time
start
stop
prophylaxi
vari
regimen
regimen
need
start
sever
week
departur
wherea
other
must
continu
travel
return
home
mani
option
malaria
prophylaxi
although
practic
decis
often
made
easier
combin
time
departur
willing
take
daili
medic
toler
potenti
side
effect
one
recommend
approach
depict
tabl
studi
suggest
travel
may
engag
highrisk
sexual
behavior
would
otherwis
includ
sex
new
partner
unprotect
sex
percentag
travel
sexual
activ
new
partner
abroad
depend
popul
survey
uk
studi
survey
travel
year
old
travel
without
partner
found
sexual
activ
rate
use
condom
consist
norwegian
studi
survey
client
sexual
transmit
infect
clinic
found
sexual
activ
rate
highrisk
sexual
activ
increas
risk
human
immunodefici
viru
hiv
hepat
b
sexual
transmit
diseas
travel
may
sex
new
partner
abroad
bring
latex
condom
studi
shown
manufactur
abroad
may
prone
breakag
popul
found
like
engag
sexual
activ
new
partner
abroad
unprotect
sex
includ
younger
travel
year
age
men
sex
men
expatri
militari
personnel
sex
tourist
defin
travel
explicit
intent
engag
sexual
activ
popul
discuss
obtain
preexposur
postexposur
prophylaxi
sexual
transmit
infect
appropri
symptom
sign
sexual
transmit
infect
dysuria
purul
drainag
pruritu
genit
lesion
discuss
patient
mani
part
world
rabi
present
dog
popul
travel
countri
univers
rabi
vaccin
dog
rare
awar
rabi
risk
rabi
transmiss
dog
bite
major
problem
africa
part
asia
central
south
america
travel
advis
avoid
dog
travel
assum
friendli
dog
travel
bitten
dog
travel
highrisk
area
need
postexposur
prophylaxi
soon
possibl
reptil
amphibian
exposur
like
travel
turtl
iguana
gecko
snake
frog
toad
preval
mani
warm
climat
may
featur
pet
zoo
hire
photograph
opportun
creatur
frequent
spread
salmonella
best
advis
avoid
decreas
salmonella
transmiss
exposur
good
hand
wash
use
antibacteri
hand
gel
must
antibacteri
hand
gel
crucial
part
travel
medic
kit
travel
diarrhea
affect
travel
resourcepoor
destin
defin
loos
stool
hour
without
cramp
nausea
fever
vomit
destin
highest
risk
south
asia
africa
latin
america
travel
develop
countri
carri
risk
lower
median
time
onset
symptom
approxim
week
arriv
destin
ill
tend
selflimit
last
sever
day
although
occasion
last
week
case
although
rare
life
threaten
travel
diarrhea
significantli
affect
plan
activ
travel
case
travel
diarrhea
identifi
caus
studi
travel
return
jamaica
identifi
caus
identifi
caus
common
pathogen
bacteri
virus
parasit
also
common
common
bacteri
caus
enterotox
escherichia
coli
follow
salmonella
speci
campylobact
jejuni
shigella
speci
common
viral
caus
rotaviru
enter
adenoviru
parasit
caus
includ
giardia
lamblia
cryptosporidium
cyclospora
entamoeba
histolytica
patient
mild
moder
travel
diarrhea
fever
hematochezia
tenesmu
diagnosi
travel
diarrhea
may
made
clinic
ground
one
recommend
approach
outlin
fig
routin
stool
cultur
reflex
order
distinguish
pathogen
nonpathogen
strain
escherichia
coli
result
stool
cultur
might
affect
manag
howev
patient
report
fever
bloodi
stool
tenesmu
cultur
warrant
patient
recent
taken
antibiot
stool
sent
test
clostridium
difficil
parasit
infect
less
common
examin
stool
ova
parasit
often
initi
indic
diarrhea
persist
week
despit
appropri
antibiot
treatment
parasit
infect
consid
set
stool
examin
ova
parasit
assess
cryptosporidium
cyclospora
antigen
test
entamoeba
histolytica
immunoassay
giardia
treatment
main
compon
volum
replet
symptom
manag
treatment
underli
infect
common
seriou
complic
travel
diarrhea
volum
deplet
mild
moder
case
broth
juic
similar
liquid
suffic
case
sever
diarrhea
oral
rehydr
solut
use
commerci
product
avail
solut
made
inexpens
mix
onehalf
tablespoon
tabl
salt
onehalf
tablespoon
bake
soda
tablespoon
sugar
l
water
second
compon
treatment
aim
help
symptom
bismuth
help
control
nausea
loperamid
help
decreas
number
loos
stool
sever
studi
shown
combin
antibiot
loperamid
safe
provid
rapid
symptom
relief
either
agent
alon
infect
must
address
antibiot
regimen
vari
selftreat
recommend
differenti
skin
lesion
return
travel
overwhelm
section
focus
common
seriou
infect
cutan
manifest
approxim
return
travel
experi
form
skin
disord
skin
disord
account
posttravel
clinic
visit
despit
travel
exot
local
mani
travelrel
skin
lesion
pedestrian
caus
travel
frequent
experi
sexual
transmit
infect
sunburn
allerg
reaction
scabi
staphylococc
streptococc
infect
chronic
skin
condit
like
acn
allerg
dermat
flare
tropic
locat
geosentinel
network
collabor
intern
societi
tropic
medicin
cdc
found
common
skinrel
diagnos
return
travel
cutan
larva
migran
clm
insect
biterel
diseas
includ
superinfect
bite
skin
abscess
allerg
reaction
tabl
leishmaniasi
dengu
account
approxim
case
geosentinel
studi
includ
differenti
diagnosi
given
potenti
sever
largest
studi
geosentinel
studi
french
studi
found
similar
result
myiasi
tungiasi
also
common
french
studi
disproportion
travel
africa
like
explain
higher
frequenc
gener
uncommon
diseas
distinct
characterist
clm
leishmaniasi
myiasi
tungiasi
describ
section
discuss
dengu
infect
defer
section
fever
return
travel
clm
caus
anim
hook
worm
found
worldwid
infect
frequent
southeast
asia
africa
south
america
caribbean
southeastern
part
unit
state
human
infect
clm
contact
ground
contamin
fece
infect
anim
gener
dog
cat
larva
penetr
human
skin
migrat
subcutan
tissu
migrat
caus
characterist
serpigin
pattern
clm
fig
rash
usual
seen
within
day
exposur
lesion
may
papular
vesiculobul
prone
bacteri
superinfect
common
locat
buttock
thigh
feet
lesion
may
associ
pruritu
pain
diagnosi
made
clinic
histori
appear
eosinophilia
rare
present
although
cutan
diseas
selflimit
treatment
shorten
durat
reduc
risk
superinfect
prefer
agent
ivermectin
although
albendazol
may
use
altern
hematogen
spread
lung
rare
complic
commonli
present
respiratori
symptom
approxim
week
cutan
erupt
specif
diagnost
test
avail
treatment
cutan
infect
leishmaniasi
present
countri
throughout
africa
asia
southern
europ
latin
america
cutan
leishmaniasi
superfici
manifest
local
recidivan
diffus
mucos
local
cutan
form
occur
expos
area
skin
start
red
papul
enlarg
form
painless
ulcer
heap
margin
granulomat
tissu
base
fig
lesion
selflimit
rate
resolut
determin
particular
infect
speci
hypopig
scar
ulcer
resolut
common
leishmaniasi
recidivan
uncommon
caus
leishmania
tropica
infect
middl
east
resolut
primari
lesion
remain
pathogen
caus
new
papul
occur
around
margin
scar
papul
appear
ulcer
heal
repeatedli
decad
patient
impair
cellmedi
immun
respons
diffus
cutan
leishmaniasi
occur
instead
primari
lesion
ulcer
organ
dissemin
macrophag
area
skin
diffus
cutan
leishmaniasi
characterist
relaps
chronic
progress
cours
may
caus
signific
deform
mucos
leishmaniasi
occur
latestag
complic
less
case
l
braziliensi
infect
endem
latin
america
month
year
primari
lesion
resolv
recurr
distant
mucos
site
may
occur
leishmaniasi
tradit
diagnos
microscop
visual
organ
tissu
sampl
burden
diseas
determin
durat
infect
chronic
lesion
lower
burden
therefor
lack
organ
necessarili
exclud
diagnosi
depend
clinic
facil
process
recommend
direct
microscopi
cultur
histolog
polymeras
chain
reaction
pcr
pcr
use
speciat
locat
travel
endem
speci
speciat
import
differ
speci
associ
differ
clinic
entiti
prognosi
tissu
sampl
obtain
skin
scrape
aspir
biopsi
prefer
biopsi
possibl
lesion
biopsi
activ
edg
like
higher
parasit
burden
treatment
goal
leishmaniasi
includ
resolut
activ
infect
reduc
scar
decreas
recurr
choic
durat
therapi
depend
manifest
cutan
versu
mucos
warrant
involv
specialist
tradit
cours
intraven
iv
pentaval
antimoni
use
day
singledos
iv
liposom
amphotericin
becom
commonli
use
myiasi
found
tropic
subtrop
area
common
present
myiasi
return
travel
furuncular
myiasi
caus
botfli
tumbu
fli
instanc
larva
penetr
skin
develop
subderm
tissu
typic
larva
per
lesion
although
multipl
lesion
may
present
patient
may
describ
enlarg
insect
bite
cm
diamet
crawl
sensat
episod
pain
near
lesion
may
serosanguin
discharg
central
punctum
small
white
structur
protrud
lesion
diagnosi
made
clinic
histori
physic
examin
remov
intact
larva
cur
differ
approach
remov
use
one
option
occlud
petroleum
jelli
skin
apertur
larva
breath
extract
larva
move
closer
surfac
get
air
fig
larva
die
occlus
difficult
remov
often
trigger
intens
inflammatori
reaction
remov
via
manual
express
extract
small
incis
prefer
possibl
like
myiasi
tungiasi
found
subtrop
tropic
destin
tungiasi
caus
femal
sand
flea
penetr
human
skin
usual
feet
hand
tungiasi
caus
skin
inflamm
sever
pain
itch
lesion
site
infect
character
black
dot
center
swollen
red
papul
surround
look
like
white
halo
flea
produc
egg
expel
host
skin
diagnosi
made
clinic
histori
physic
examin
confirm
made
identif
organ
remov
treatment
achiev
remov
flea
fever
return
travel
herald
signific
ill
geosentinel
studi
fever
chief
complaint
patient
seek
posttravel
care
studi
patient
fever
requir
hospit
global
return
develop
world
approxim
travel
experi
fever
travel
fever
vaccineprevent
infect
falciparum
malaria
prevent
chemoprophylaxi
underscor
import
pretravel
visit
geosentinel
studi
common
caus
fever
return
travel
malaria
dengu
rickettsi
infect
typhoid
paratyphoid
fever
otherwis
known
enter
fever
depend
travel
destin
leptospirosi
chikungunya
fever
hepat
also
consid
caus
febril
system
ill
return
travel
return
travel
present
fever
diagnosi
malaria
must
first
consid
malaria
possibl
base
time
locat
travel
obtain
thin
thick
smear
repeat
serial
blood
smear
everi
hour
hour
malaria
evalu
neg
unlik
base
factor
evalu
base
local
symptom
sign
would
febril
patient
local
symptom
sign
consid
dengu
rickettsiosi
enter
fever
caus
fever
base
locat
travel
patient
visit
malaria
endem
area
last
year
report
fever
evalu
malaria
even
afebril
present
geosentinel
studi
travel
sought
medic
attent
fever
eventu
diagnos
malaria
thirtythre
percent
patient
febril
ill
eventu
die
malaria
malaria
caus
protozoan
speci
genu
plasmodium
falciparum
vivax
oval
malaria
knowlesi
anophel
mosquito
vector
malaria
introduct
organ
mosquito
bite
incub
period
depend
malaria
speci
gener
day
although
p
vivax
oval
present
year
exposur
latent
form
hide
liver
fever
caus
intracellular
pathogen
burst
erythrocyt
uncompl
malaria
character
absenc
endorgan
dysfunct
although
associ
anemia
jaundic
addit
criteria
uncompl
malaria
includ
parasit
burden
defin
percent
infect
erythrocyt
less
abil
take
medic
oral
complic
malaria
usual
caus
p
falciparum
although
increasingli
p
vivax
p
knowlesi
recogn
caus
complic
malaria
cerebr
malaria
defin
alter
mental
statu
seizur
coma
risk
factor
includ
extrem
age
immunocompromis
statu
includ
hiv
asplenia
pregnanc
without
treatment
cerebr
malaria
uniformli
fatal
thu
prompt
recognit
initi
therapi
critic
even
therapi
mortal
remain
patient
may
perman
cognit
sequela
infect
initi
patient
malaria
may
experi
high
fever
irregular
interv
throughout
day
infect
progress
ruptur
infect
red
cell
tend
synchron
lead
characterist
daytoday
fever
pattern
pattern
fever
depend
particular
speci
malaria
p
falciparum
vivax
oval
roughli
cycl
p
malaria
hour
symptom
sign
pathognomon
malaria
clinic
featur
may
suggest
malaria
includ
fever
without
local
symptom
enlarg
spleen
thrombocytopenia
hyperbilirubinemia
pathophysiolog
malaria
relat
cytoadher
red
blood
cell
factor
lead
small
infarct
capillari
leakag
organ
dysfunct
clinic
manifest
may
includ
alter
mental
statu
seizur
acut
respiratori
distress
syndrom
metabol
acidosi
renal
failur
hemoglobinuria
blackwat
fever
hepat
failur
coagulopathi
without
dissemin
intravascular
coagul
sever
anemia
massiv
intravascular
hemolysi
hypoglycemia
classic
diagnost
test
malaria
examin
giemsastain
blood
smear
light
microscopi
fig
two
differ
smear
prepar
order
concern
malaria
thin
smear
allow
speciat
stage
parasit
life
cycl
thick
smear
allow
sensit
red
blood
cell
lyse
therefor
parasit
releas
area
compar
thin
smear
first
test
posit
infect
patient
given
natur
cyclic
parasitemia
exclus
malaria
requir
smear
evalu
everi
hour
hour
light
microscopi
sever
disadvantag
labor
intens
requir
consider
train
time
consum
rapid
diagnost
test
detect
malaria
antigen
small
amount
blood
immunochromatograph
assay
monoclon
antibodi
direct
parasit
antigen
impregn
test
strip
commerci
test
manufactur
differ
combin
target
antigen
suit
local
malaria
epidemiolog
us
food
drug
administr
approv
first
rapid
detect
test
use
unit
state
posit
rapid
detect
test
result
must
confirm
microscopi
microscopi
also
import
speciat
determin
parasit
burden
pcr
avail
use
initi
evalu
pcr
use
set
determin
speci
parasit
diagnosi
malaria
establish
treatment
malaria
influenc
patientspecif
factor
age
background
immun
pregnanc
abil
take
oral
medic
speciesspecif
factor
local
factor
drug
resist
pattern
govern
treatment
guidelin
toler
drug
avail
tabl
medic
use
treatment
patient
use
prophylaxi
case
drugresist
strain
select
nonfalciparum
malaria
vivax
malaria
oval
gener
treat
chloroquin
chloroquineresist
vivax
report
recent
papua
new
guinea
indonesia
chloroquineresist
malaria
report
sumatra
addit
primaquin
requir
p
vivax
oval
infect
erad
parasit
surviv
liver
combin
therapi
gener
prevent
relaps
p
vivax
oval
infect
primaquinetoler
strain
p
vivax
emerg
oceania
east
africa
longer
higher
dose
primaquin
requir
area
radic
cure
p
falciparum
treatment
depend
sensit
pattern
particular
area
infect
acquir
p
falciparum
origin
central
america
west
panama
canal
haiti
dominican
republ
much
middl
east
treat
chloroquin
howev
develop
resist
regimen
p
falciparum
acquir
elsewher
treat
atovaquoneproguanil
artemetherlumefantrin
quinin
plu
doxycyclin
tetracyclin
clindamycin
mefloquin
mefloquin
use
patient
return
cambodia
thailand
case
mefloquin
resist
report
complic
diseas
pregnanc
sever
nausea
vomit
necessit
admiss
hospit
involv
specialist
standard
treatment
sever
diseas
includ
quinidin
glucon
plu
doxycyclin
tetracyclin
clindamycin
use
artesun
becom
common
requir
involv
cdc
random
control
trial
endem
region
shown
reduct
mortal
artesunatebas
regimen
compar
quininebas
regimen
exchang
transfus
consid
patient
parasit
burden
greater
alter
mental
statu
pulmonari
edema
renal
complic
cdc
web
site
http
wwwcdcgovmalariadiagnosistreatmenttreat
html
provid
uptod
inform
regard
frequent
chang
epidemiolog
resist
pattern
describ
obtain
artesun
unit
state
web
site
review
initi
malaria
treatment
dengu
endem
puerto
rico
latin
american
africa
southeast
asia
period
outbreak
samoa
guam
dengu
viru
singlestrand
rna
viru
serotyp
clinic
descript
mean
infect
serotyp
provid
immun
particular
serotyp
viru
carri
aed
mosquito
silent
daytim
feeder
bite
frequent
go
unnot
incub
period
rang
day
therefor
effect
exclud
caus
febril
ill
travel
whose
symptom
start
day
return
viral
host
characterist
influenc
clinic
present
dengu
sever
theori
combin
factor
result
sever
present
evid
suggest
sever
dengu
fever
occur
individu
infect
dengu
time
theori
includ
hypothesi
differ
dengu
virus
inher
differ
level
virul
sever
clinic
present
involv
abnorm
tcell
respons
autoimmun
phenomena
dengu
diseas
occur
spectrum
diseas
sever
guidelin
categor
dengu
diseas
nonsever
sever
nonsever
dengu
fever
acut
febril
ill
follow
manifest
headach
retroorbit
pain
myalgia
arthralgia
prompt
name
breakbon
fever
rash
leucopenia
mild
hemorrhag
symptom
triad
skin
rash
fig
thrombocytopenia
leukopenia
febril
return
travel
suggest
dengu
infect
nonsever
group
subdivid
presenc
warn
sign
warn
sign
usual
aris
day
fever
may
indic
develop
sever
dengu
fever
warn
sign
includ
mucos
bleed
emesi
hematemesi
sever
abdomin
pain
pain
hepatomegali
breath
discomfort
lethargi
fatigu
symptom
often
occur
patient
defervesc
sever
dengu
defin
plasma
leakag
fluid
accumul
respiratori
distress
sever
bleed
organ
impair
patient
sever
dengu
manifest
mani
warn
sign
sever
dengu
seem
occur
less
frequent
among
travel
nativ
popul
nativ
popul
might
suscept
like
infect
sequenti
dengu
serotyp
secondari
infect
hypothesi
altern
explan
expos
travel
younger
adult
less
like
develop
sever
diseas
compar
old
young
diagnosi
often
made
base
clinic
present
serolog
molecular
test
avail
choic
confirmatori
diagnost
test
depend
time
patient
present
patient
present
least
day
acut
febril
ill
measur
antidengu
igm
recommend
day
antidengu
igm
neg
clinic
suspicion
remain
high
pcr
dengu
viral
rna
perform
although
viral
rna
clear
bloodstream
earli
cours
infect
support
care
manag
avail
treatment
dengu
rickettsiosi
term
use
spectrum
diseas
caus
intracellular
bacteria
rickettsia
invad
endotheli
cell
produc
vascul
multipl
ectoparasit
vector
rickettsia
includ
lice
tick
flea
mite
rickettsiosi
divid
main
biogroup
typhu
spot
fever
scrub
typhu
common
rickettsios
seen
travel
includ
murin
typhu
mediterranean
spot
fever
african
tick
bite
fever
scrub
typhu
diseas
caus
differ
speci
carri
differ
vector
differ
geograph
distribut
differ
clinic
present
sequela
combin
fever
cutan
erupt
fig
suggest
rickettsiosi
travel
return
endem
region
rocki
mountain
spot
fever
rickettsi
infect
primarili
diagnos
clinic
base
epidemiolog
histori
physic
examin
find
rickettsiosi
confirm
method
isol
organ
serolog
pcr
immunolog
detect
tissu
sampl
firstlin
treatment
rickettsios
doxycyclin
presumpt
treatment
recommend
whenev
diagnosi
suspect
make
diagnosi
acut
phase
difficult
enter
fever
encompass
typhoid
paratyphoid
fever
common
part
world
except
industri
region
north
america
western
europ
australia
japan
salmonella
enterica
serotyp
typhi
paratyphi
caus
clinic
indistinguish
entiti
howev
vaccin
serotyp
typhi
paratyphi
gramneg
organ
ingest
surviv
gastric
acid
invad
gut
epithelium
invad
lymphat
tissu
spread
hematogen
lymphat
incub
period
depend
amount
pathogen
ingest
host
age
immun
statu
gener
day
classic
clinic
triad
abdomin
pain
fever
chill
patient
may
experi
increment
increas
fever
first
week
increas
rate
c
c
day
plateau
fever
rang
week
follow
gener
plateau
phase
seen
travel
oppos
endem
popul
develop
countri
travel
apt
seek
care
earlier
stage
examin
rel
bradycardia
may
seen
well
hepatosplenomegali
although
neither
find
specif
rose
spot
lightli
erythemat
nonblanch
plaqu
mm
diamet
seen
patient
typhoid
children
patient
hiv
like
present
diarrhea
wherea
adult
like
complain
constip
complic
occur
patient
particularli
like
patient
ill
week
among
numer
complic
gastrointestin
bleed
intestin
perfor
typhoid
encephalopathi
enter
fever
diagnos
blood
stool
cultur
cultur
may
neg
antibiot
given
obtain
sampl
blood
cultur
sensit
standard
diagnost
test
stool
cultur
sensit
cultur
remain
neg
diagnosi
remain
uncertain
bone
marrow
biopsi
use
test
sensit
serolog
test
use
firstlin
treatment
enter
fever
day
quinolon
except
norfloxacin
antibiot
therapi
firstlin
agent
quinoloneresist
typhoid
determin
azithromycin
thirdgener
cephalosporin
long
highdos
cours
quinolon
propos
cdc
recommend
inject
thirdgener
cephalosporin
modestli
effect
vaccin
avail
typhoid
fever
parent
version
take
advantag
iggmedi
cell
immun
oral
form
take
advantag
iga
secretori
immun
best
parent
vaccin
efficaci
prevent
typhoid
fever
oral
vaccin
estim
less
effect
respiratori
infect
occur
travel
geosentinel
studi
found
common
diagnosi
uri
nonspecifi
uri
follow
pharyng
tonsil
common
diagnos
lower
respiratori
tract
infect
bronchiti
pneumonia
influenza
thu
travel
return
respiratori
complaint
diagnos
common
develop
world
outbreak
often
link
group
set
cruis
tour
group
sever
pathogen
associ
outbreak
includ
influenza
legionella
coronaviru
histoplasma
risk
tuberculosi
among
immunocompet
travel
low
identif
specif
agent
outpati
set
caus
respiratori
symptom
immunocompet
host
usual
unnecessari
patient
influenza
treatment
oseltamivir
might
appropri
effect
specif
therapi
noninfluenza
respiratori
virus
immunocompet
adult
treatment
bacteri
pneumonia
base
antibiot
sensit
local
guidelin
fiftynin
countri
restrict
regard
travel
hiv
visit
countri
includ
deport
hiv
statu
discov
four
countri
bar
entri
patient
hiv
sudan
yemen
unit
arab
emir
brunei
uptod
inform
avail
http
wwwunaidsorg
review
travel
kill
inactiv
vaccin
safe
hivposit
patient
maxim
effect
vaccin
administ
count
peak
effect
antiretrovir
therapi
increas
incid
preval
sever
malaria
hivinfect
individu
although
special
precaut
patient
hiv
would
indic
immunocompet
patient
ie
net
deet
strict
prophylaxi
complianc
increas
risk
infect
sever
diseas
underscor
import
incid
clinic
episod
malaria
found
higher
individu
cell
count
less
cellsml
cell
count
greater
cellsml
patient
less
advis
postpon
travel
count
rebound
pharmaci
review
possibl
interact
antiretrovir
medic
malaria
prophylaxi
routin
antimicrobi
prophylaxi
travel
diarrhea
patient
hiv
recommend
sever
immunosuppress
present
trip
postpon
prevent
regimen
dailydos
quinolon
rifaximin
appropri
case
immunocompet
patient
hivinfect
travel
develop
travel
diarrhea
treat
ciprofloxacin
howev
diarrhea
persist
addit
stool
sampl
submit
giardia
antigen
specif
instruct
microsporidia
cryptosporidium
parvum
stain
ova
parasit
p
examin
look
cyclospora
cayatenensi
isospora
belli
greatest
risk
infect
month
transplant
immunosuppress
highest
travel
postpon
period
laps
patient
antireject
drug
avoid
volum
deplet
mani
antireject
drug
nephrotox
like
caus
acut
kidney
injuri
therefor
patient
antireject
drug
counsel
start
volum
replet
given
antibiot
loperamid
start
promptli
even
mild
travel
diarrhea
malaria
prophylaxi
may
interact
antireject
drug
thu
level
need
monitor
pharmacist
departur
splenectomi
whether
function
surgic
contraind
vaccin
addit
asplen
patient
particularli
suscept
encapsul
organ
alreadi
vaccin
streptococcu
pneumonia
within
year
neisseria
mening
within
year
haemophilu
influenza
vaccin
administ
travel
visit
travel
previous
receiv
although
patient
asplenia
higher
risk
influenza
may
predispos
invas
streptococcu
pneumonia
thu
also
immun
flu
pretravel
visit
alreadi
done
patient
asplenia
promptli
treat
antibiot
onset
febril
ill
anim
bite
given
travel
may
readi
access
medic
care
asplen
patient
given
cours
amoxicillinclauvan
adequ
initi
treatment
fever
anim
bite
prophylaxi
take
antibiot
set
adjunct
seek
prompt
medic
care
replac
distinct
need
explicitli
state
asplen
patient
also
wear
alert
bracelet
asplen
patient
malaria
may
delay
clearanc
parasit
bloodstream
despit
appropri
treatment
receiv
followup
blood
smear
treatment
complet
patient
take
greater
equival
mgd
prednison
week
consid
immunosuppress
live
vaccin
administ
immun
respons
inactiv
vaccin
may
insuffici
physician
wait
month
steroid
discontinu
administ
vaccin
pauciti
data
administr
live
vaccin
patient
tumor
necrosi
factor
tnfa
inhibitor
avoid
patient
differenti
diagnosi
patient
corticosteroid
tnfa
inhibitor
necessarili
broad
may
present
atyp
addit
patient
increas
risk
infect
otherwis
commonli
seen
travel
includ
tuberculosi
invas
fungal
diseas
cdc
consid
patient
alkyl
agent
cyclophosphamid
antimetabolit
azathioprin
chemotherapeut
agent
includ
weekli
methotrex
exclud
tamoxifen
sever
immunosuppress
live
vaccin
administ
least
month
therapi
discontinu
pretravel
clinic
visit
integr
part
diseas
prevent
travel
intend
trip
review
depth
patient
assess
risk
particular
certain
countri
condit
appropri
immun
review
administ
uptod
recommend
list
locat
cdc
web
site
patient
counsel
insect
bite
travel
diarrhea
avoid
measur
safe
sex
practic
reinforc
patient
given
antibiot
take
case
moder
sever
travel
diarrhea
travel
diarrhea
common
gener
occur
day
arriv
viral
caus
well
bacteri
caus
usual
selflimit
last
sever
day
mild
diarrhea
treat
volum
replet
symptom
manag
loperamid
bismuth
symptom
last
longer
week
bloodi
diarrhea
present
stool
cultur
obtain
diarrhea
present
week
despit
antibacteri
treatment
parasit
caus
consid
stool
p
examin
cryptosporidium
cyclospora
forth
sent
skin
lesion
return
travel
often
secondari
condit
commonli
seen
develop
countri
clm
develop
pathognomon
serpigin
appear
day
larva
enter
human
host
diagnosi
clinic
treat
ivermectin
albendazol
leishmaniasi
differ
cutan
manifest
interv
infect
clinic
manifest
rang
week
year
depend
particular
speci
host
immun
statu
leishmaniasi
diagnos
obtain
tissu
sampl
perform
microscopi
histolog
pcr
cultur
treatment
lengthi
involv
specialist
myiasi
tungiasi
diagnos
clinic
treat
remov
parasit
fever
return
travel
malaria
prove
otherwis
present
month
return
endem
area
evalu
involv
thin
thick
blood
smear
decis
whether
admit
treatment
base
speci
resist
pattern
dengu
incub
period
less
week
exclud
patient
present
fever
day
return
dengu
spectrum
sever
treatment
support
incub
period
clinic
present
rickettsiosi
depend
particular
infect
speci
diagnosi
primarili
clinic
treatment
doxycyclin
enter
fever
present
abdomin
pain
fever
chill
incub
gener
week
less
like
patient
present
week
return
endem
countri
blood
cultur
diagnost
standard
infect
treat
quinolon
patient
underli
immunosuppress
need
receiv
tailor
advic
pretravel
clinic
visit
immunosuppress
patient
may
contraind
live
vaccin
impair
immun
respons
inact
vaccin
return
differenti
return
immunosuppress
patient
must
broader
may
present
atyp
also
suscept
wider
rang
pathogen
travel
medicin
continu
grow
intern
tourism
patient
medic
complex
increas
articl
reflect
state
disciplin
new
recommend
immun
resist
pattern
treatment
modal
constantli
chang
cdc
maintain
help
web
site
patient
physician
thought
prepar
prevent
risk
minim
travel
continu
safe
possibl
